Nitric oxide (SB 204)

Drug Profile

Nitric oxide (SB 204)

Alternative Names: SB-204

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novan Inc
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifungals; Antihypertensives; Antivirals; Free radicals; Macromolecular substances; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acne vulgaris
  • Discontinued Staphylococcal infections

Most Recent Events

  • 07 Nov 2017 Novan plans a phase III trial for Acne vulgaris in 2018 before the planned NDA submission
  • 25 Sep 2017 Novan plans a pivotal trial for Acne vulgaris in USA
  • 07 Jul 2017 Pharmacodynamics data from an ex-vivo study released by Novan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top